Bepridil hydrochloride
CAS: 68099-86-5
Rif. 3D-TCA09986
10mg | Fuori produzione | ||
25mg | Fuori produzione | ||
50mg | Fuori produzione | ||
100mg | Fuori produzione | ||
250mg | Fuori produzione |
Informazioni sul prodotto
- 1-Pyrrolidineethanamine, beta-((2-methylpropoxy)methyl)-N-phenyl-N-(phenylmethyl)-, monohydrochloride
- 1-Pyrrolidineethanamine, β-[(2-methylpropoxy)methyl]-N-phenyl-N-(phenylmethyl)-, hydrochloride (1:1)
- 1-Pyrrolidineethanamine, β-[(2-methylpropoxy)methyl]-N-phenyl-N-(phenylmethyl)-, monohydrochloride
- 1978Cerm
- Bepricor
- Bepridil HCl
- Cordium
- N-Benzyl-beta-((2-methylpropoxy)methyl)-N-phenylpyrrolidine-1-ethylamine monohydrochloride
- N-benzyl-N-[3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl]aniline hydrochloride (1:1)
- N-benzyl-N-[3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl]aniline hydrochloride hydrate
- Vedi altri sinonimi
- Vascor
Bepridil is a fatty acid that is structurally related to the beta-blocker propranolol. It has been shown to be effective in the treatment of anginal attacks and ventricular dysfunction. Bepridil inhibits the enzyme phosphodiesterase, which regulates the breakdown of cyclic nucleotides (cAMP and cGMP). This inhibition leads to an increase in cAMP and a decrease in cGMP levels, which results in an increase in intracellular calcium concentrations and increased cardiac contractility. Bepridil has also been shown to have cancer therapeutic effects on prostate cancer cells. The mechanism of action for these effects is unknown, but may be due to its ability to act as a diagnostic agent for cancer.